Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia
Alkermes(ALKS) Prnewswire·2024-04-09 19:00ALKS 2680概念验证研究结果 - Alkermes plc宣布了ALKS 2680在纳科雷普症2型（NT2）和特发性嗜睡症（IH）队列的1b期概念验证研究中的积极头条结果[1] - ALKS 2680在NT2患者中表现出改善清醒度的效果，且剂量反应明显[2] - ALKS 2680在IH患者中也表现出改善清醒度的效果，且剂量反应明显[5]